2024
Acute pancreatitis: pathogenesis and emerging therapies
Zaman S, Gorelick F. Acute pancreatitis: pathogenesis and emerging therapies. Journal Of Pancreatology 2024, 7: 10-20. PMID: 38524855, PMCID: PMC10959536, DOI: 10.1097/jp9.0000000000000168.Peer-Reviewed Original ResearchAcute pancreatitisSevere inflammatory disordersLimited treatment optionsLong-term outcomesPotential treatment benefitsPromising new therapyDisease mechanismsPotential therapeutic targetEmerging TherapiesAcute injuryInflammatory disordersPharmacologic interventionsTreatment optionsTreatment benefitPotential therapyNew therapiesSpecific treatmentTherapeutic targetNew treatmentsTherapyPancreatitisTreatmentComplicationsPathogenesisInjury
2019
Precision Medicine in Pancreatic Disease-Knowledge Gaps and Research Opportunities: Summary of a National Institute of Diabetes and Digestive and Kidney Diseases Workshop.
Lowe ME, Andersen DK, Caprioli RM, Choudhary J, Cruz-Monserrate Z, Dasyam AK, Forsmark CE, Gorelick FS, Gray JW, Haupt M, Kelly KA, Olive KP, Plevritis SK, Rappaport N, Roth HR, Steen H, Swamidass SJ, Tirkes T, Uc A, Veselkov K, Whitcomb DC, Habtezion A. Precision Medicine in Pancreatic Disease-Knowledge Gaps and Research Opportunities: Summary of a National Institute of Diabetes and Digestive and Kidney Diseases Workshop. Pancreas 2019, 48: 1250-1258. PMID: 31688587, PMCID: PMC7282491, DOI: 10.1097/mpa.0000000000001412.Peer-Reviewed Original ResearchConceptsPancreatic diseasePrecision medicineCurrent precision medicine approachesKidney Diseases workshopProspective clinical trialsNational InstitutePrecision medicine approachHealth care systemKidney diseaseRisk factorsClinical trialsFatal illnessMulticenter effortsMedicine approachDiseaseCare systemDisease mechanismsDiabetesPatient data setsMedicinePersonalized medicinePrecision imagingPatientsTherapyIllnessCELA2A mutations predispose to early-onset atherosclerosis and metabolic syndrome and affect plasma insulin and platelet activation
Esteghamat F, Broughton JS, Smith E, Cardone R, Tyagi T, Guerra M, Szabó A, Ugwu N, Mani MV, Azari B, Kayingo G, Chung S, Fathzadeh M, Weiss E, Bender J, Mane S, Lifton RP, Adeniran A, Nathanson MH, Gorelick FS, Hwa J, Sahin-Tóth M, Belfort-DeAguiar R, Kibbey RG, Mani A. CELA2A mutations predispose to early-onset atherosclerosis and metabolic syndrome and affect plasma insulin and platelet activation. Nature Genetics 2019, 51: 1233-1243. PMID: 31358993, PMCID: PMC6675645, DOI: 10.1038/s41588-019-0470-3.Peer-Reviewed Original ResearchConceptsEarly-onset atherosclerosisMetabolic syndromeMetabolic syndrome traitsWhole-exome sequence analysisAttractive therapeutic targetPlatelet hyperactivationInsulin levelsPlasma insulinPlasma levelsInsulin sensitivityInsulin secretionTherapeutic targetPlatelet activationDisease mechanismsSyndrome traitsAtherosclerosisFunction mutationsSyndromeNovel lossInsulinMutationsSecretion
2017
Do Animal Models of Acute Pancreatitis Reproduce Human Disease?
Gorelick FS, Lerch MM. Do Animal Models of Acute Pancreatitis Reproduce Human Disease? Cellular And Molecular Gastroenterology And Hepatology 2017, 4: 251-262. PMID: 28752114, PMCID: PMC5518169, DOI: 10.1016/j.jcmgh.2017.05.007.Peer-Reviewed Original ResearchAcute pancreatitisBiological disease mechanismsNonmalignant gastrointestinal diseasesPathophysiological disease mechanismsDisease mechanismsPotential therapeutic targetPaucity of dataHospital admissionCommon causeExperimental pancreatitis modelGastrointestinal diseasesPancreatitis modelTherapeutic targetAnimal modelsNatural historySpecific causesDiseaseDisease modelsPancreatitisDisease developmentUnderlying cellMolecular mechanismsHuman diseasesCauseLimited information